MCID: CNJ013
MIFTS: 66

Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Conjunctivitis

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 11 75 28 53 2 43 14 63 16 71 31 33
Acute Adenoviral Follicular Conjunctivitis 33
Inclusion Conjunctivitis of the Adult 33
Swimming-Pool Conjunctivitis 33
Inflammation of Conjunctiva 33
Adenoviral Conjunctivitis 33
Koch-Weeks Conjunctivitis 33
Acute Conjunctivitis 33
Catarrhal Ophthalmia 33
Eye Catarrh 33
Madras Eye 11
Ophthalmia 33

Classifications:



External Ids:

Disease Ontology 11 DOID:6195
ICD9CM 34 372.30
MeSH 43 D003231
NCIt 49 C34504
SNOMED-CT 68 193857008
UMLS 71 C0009763

Summaries for Conjunctivitis

PubMed Health : 63 Conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other. Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks. Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary: Conjunctivitis, also known as acute adenoviral follicular conjunctivitis, is related to giant papillary conjunctivitis and bacterial conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pheniramine and Iodine have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and skin, and related phenotypes are homeostasis/metabolism and growth/size/body region

CDC: 2 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Disease Ontology: 11 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

Wikipedia: 75 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Related Diseases for Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1129)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 32.8 RNASE3 IL5 IL4 IL13 CXCL8 CCL11
2 bacterial conjunctivitis 32.7 TNF IL6 IL10 CXCL8
3 blepharoconjunctivitis 32.6 IL4 IL13
4 papillary conjunctivitis 32.5 RNASE3 IL5 IL4 IL13 CXCL8 CCL11
5 vernal conjunctivitis 32.3 IL4 CCL11
6 allergic conjunctivitis 32.1 TNF RNASE3 IL6 IL5 IL4 IL33
7 severe cutaneous adverse reaction 32.1 TNF IL6 IFNG
8 pollen allergy 31.9 IL5 IL4 IL13 IL10
9 tularemia 31.8 TNF TLR4 IL6
10 measles 31.8 TLR4 TLR3 IL6 IL2
11 graves ophthalmopathy 31.8 TNF IL6 IFNG ICAM1
12 chronic conjunctivitis 31.8 TNF RNASE3 IL6 IL5 IL4 IL33
13 periodic fever, familial, autosomal dominant 31.8 TNF NLRP3 IL6
14 avian influenza 31.7 TNF TLR3 IL6 IL10 CXCL8 CCL2
15 vernal keratoconjunctivitis 31.6 RNASE3 IL4 IL13 CCL11
16 allergic rhinitis 31.5 RNASE3 IL5 IL4 IL13 IL10 IGHE
17 trachoma 31.5 TNF IL6 IL4 IL10
18 trichinosis 31.5 TNF IL6 IL5 IL4 IL13 IL10
19 chronic rhinitis 31.4 RNASE3 IL5 IL4 IL33 IL13 HRH1
20 haemophilus influenzae 31.4 TNF CXCL8
21 keratoconjunctivitis 31.3 TNF RNASE3 IL5 IL4 IL2 IL13
22 panuveitis 31.3 TNF IL6 IL10 IFNG
23 keratitis, hereditary 31.3 TNF TLR4 NLRP3 IL6 IL10 CXCL8
24 chlamydia 31.3 TNF TLR4 IL6 IL5 IL4 IL10
25 rubella 31.2 TNF TLR4 TLR3 IL6 IL5 IL4
26 choroiditis 31.1 TNF IL10 IFNG
27 blepharitis 31.0 TNF IL6 IL4 IL2 IL13 CXCL8
28 urethritis 31.0 TNF TLR4 IL6 IL10 CXCL8
29 posterior uveitis 31.0 TNF IL6 IL5 IL2 IL13
30 corneal ulcer 30.9 TNF IL6 CCL11
31 dry eye syndrome 30.9 TNF IL6 IL10 ICAM1 CXCL8
32 bullous pemphigoid 30.8 TNF RNASE3 IL6 IL5 IL4 IGHE
33 endophthalmitis 30.8 TNF PLG IL6 ICAM1 CXCL8
34 eye disease 30.7 TNF TLR4 TLR3 PLG NLRP3 IL6
35 iritis 30.7 TNF IL6 IL10
36 cellulitis 30.7 TNF RNASE3 IL6 IL5 CXCL8
37 anterior uveitis 30.7 TNF TLR4 IL6 IL2 IL10 IFNG
38 scleritis 30.7 TNF IL5 IL4 IFNG CCL2
39 ige responsiveness, atopic 30.7 RNASE3 IL5 IL4 IL13 IL10 IGHE
40 neovascular glaucoma 30.6 PLG IL6 CXCL8 CCL2
41 spondyloarthropathy 1 30.6 TNF TLR4 IL6 IL10
42 pharyngitis 30.6 TNF NLRP3 IL6 CXCL8
43 exanthem 30.6 TNF NLRP3 IL6 IL4 IL2 IL10
44 dacryoadenitis 30.6 IL4 IL13 IL10
45 hypereosinophilic syndrome 30.6 RNASE3 IL5 IL4 IL2 IL13 IL10
46 endometritis 30.5 TNF TLR4 IL6 CXCL8
47 respiratory syncytial virus infectious disease 30.5 IL5 IL13
48 hydrocephalus 30.5 TNF TLR4 IL10 IFNG
49 rhinitis 30.5 TNF TLR4 RNASE3 IL6 IL5 IL4
50 hypopyon 30.5 TNF IL6 IL10

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease, Familial, 1 Blepharitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis

Symptoms & Phenotypes for Conjunctivitis

UMLS symptoms related to Conjunctivitis:


bloodshot eye; conjunctival congestion; redness of eye; discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.44 CCL2 HRH1 ICAM1 IFNG IL10 IL13
2 growth/size/body region MP:0005378 10.4 CCL2 HRH1 ICAM1 IFNG IL10 IL13
3 immune system MP:0005387 10.39 CCL11 CCL2 HRH1 ICAM1 IFNG IGHE
4 nervous system MP:0003631 10.38 CCL2 ICAM1 IFNG IL10 IL13 IL33
5 digestive/alimentary MP:0005381 10.34 CCL2 ICAM1 IFNG IL10 IL13 IL2
6 liver/biliary system MP:0005370 10.33 CCL2 HRH1 IFNG IL10 IL2 IL4
7 neoplasm MP:0002006 10.32 CCL2 ICAM1 IFNG IL10 IL2 IL5
8 cellular MP:0005384 10.29 CCL2 ICAM1 IFNG IL10 IL13 IL2
9 muscle MP:0005369 10.26 CCL2 HRH1 ICAM1 IFNG IL10 IL13
10 endocrine/exocrine gland MP:0005379 10.25 ICAM1 IFNG IL10 IL13 IL2 IL33
11 respiratory system MP:0005388 10.22 CCL11 IFNG IL10 IL13 IL2 IL33
12 reproductive system MP:0005389 10.21 CCL2 IFNG IL10 IL13 IL2 IL33
13 cardiovascular system MP:0005385 10.2 CCL2 ICAM1 IFNG IL10 IL2 IL33
14 no phenotypic analysis MP:0003012 10.18 IFNG IGHE IL10 IL13 IL2 IL33
15 hematopoietic system MP:0005397 10.11 CCL11 CCL2 HRH1 ICAM1 IFNG IGHE
16 skeleton MP:0005390 10.02 CCL2 IFNG IL10 IL13 IL33 IL4
17 vision/eye MP:0005391 9.96 CCL2 ICAM1 IFNG IL10 IL2 IL4
18 mortality/aging MP:0010768 9.83 CCL2 HRH1 ICAM1 IFNG IL10 IL13
19 integument MP:0010771 9.36 CCL2 ICAM1 IFNG IL10 IL13 IL4

Drugs & Therapeutics for Conjunctivitis

PubMed Health treatment related to Conjunctivitis: 63

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection , even though conjunctivitis is more commonly caused by viruses . But antibiotics are only effective against bacteria , and have no effect on viruses. If the infection is viral, only the symptoms can be treated. Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful. If conjunctivitis is caused by an allergy , it can be treated with allergy medicine such as antihistamines .

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Iodine Approved, Investigational Phase 4 7553-56-2 807
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
5
Loteprednol etabonate Approved, Experimental Phase 4 82034-46-6, 129260-79-3 22227703 9865442 444025
6
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
8
Alcaftadine Approved Phase 4 147084-10-4 19371515
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
12
Montelukast Approved Phase 4 158966-92-8 5281040
13
Dipivefrin Approved Phase 4 52365-63-6 3105
14
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
15
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
16
Ethinylestradiol Approved Phase 4 57-63-6 5991
17
Polyestradiol phosphate Approved Phase 4 28014-46-2
18
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
19
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
22
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
23
Emedastine Approved Phase 4 87233-61-2 3219
24
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
25
Polymyxin B Approved, Vet_approved Phase 4 1405-20-5, 1404-26-8 4868
26
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
27
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
28
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
29
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
30
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350 164522
31
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
32
Phenylephrine Approved Phase 4 59-42-7 6041
33
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
34
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
35
Maleic acid Experimental, Investigational Phase 4 110-16-7, 110-17-8 444266 444972
36
Cadexomer iodine Experimental Phase 4 94820-09-4
37
Tranilast Investigational Phase 4 53902-12-8 5282230
38
Spaglumic acid Experimental Phase 4 3106-85-2, 4910-46-7 188803 210320
39 Blood Substitutes Phase 4
40 Anti-Infective Agents Phase 4
41 Anti-Infective Agents, Local Phase 4
42 Plasma Substitutes Phase 4
43 Anti-Bacterial Agents Phase 4
44 Antineoplastic Agents, Hormonal Phase 4
45 Neuroprotective Agents Phase 4
46 Hormones Phase 4
47 Hormone Antagonists Phase 4
48 Antiemetics Phase 4
49 glucocorticoids Phase 4
50 Gastrointestinal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 374)
# Name Status NCT ID Phase Drugs
1 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
4 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
5 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
6 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
7 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
8 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ® (Placebo)
9 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
10 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
11 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
12 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
13 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
14 DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis Completed NCT04708821 Phase 4 Dexamethasone ophthalmic insert 0.4Mg;0.2% loteprednol etabonate ophthalmic suspension;olopatadine hydrochloride ophthalmic solution 0.7%
15 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
16 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
17 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
18 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
19 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
20 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
21 A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis Completed NCT05265910 Phase 4 olopatadine hydrochloride ophthalmic solution 0.7%;loratadine 10 mg;Tears Naturale;Placebo
22 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
23 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
24 A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis Completed NCT05314621 Phase 4 olopatadine hydrochloride ophthalmic solution 0.7%);Fluticasone Propionate;Tears Naturale;Saline nasal spray
25 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
26 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
27 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
28 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
29 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Completed NCT01346371 Phase 4 Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
30 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
31 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
32 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine
33 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
34 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
35 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
36 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
37 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
38 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
39 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
40 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
41 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
42 A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. Completed NCT00581542 Phase 4 moxifloxacin;polytrim
43 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
44 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
45 Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
46 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
47 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
48 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
49 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
50 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cromolyn
Cromolyn Sodium
Oxymetazoline
Oxymetazoline hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate

Cochrane evidence based reviews: conjunctivitis

Genetic Tests for Conjunctivitis

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 28

Anatomical Context for Conjunctivitis

Organs/tissues related to Conjunctivitis:

MalaCards : Eye, Salivary Gland, Skin, T Cells, Thymus, Bone Marrow, Lymph Node

Publications for Conjunctivitis

Articles related to Conjunctivitis:

(show top 50) (show all 14170)
# Title Authors PMID Year
1
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 53 62
20361659 2009
2
Traffic-related outdoor air pollution and respiratory symptoms in children: the impact of adjustment for exposure measurement error. 53 62
18379431 2008
3
IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens-induced papillary conjunctivitis (CLPC). 53 62
18327049 2008
4
[Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases]. 53 62
17277873 2006
5
[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis]. 53 62
16491868 2006
6
Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. 53 62
15245511 2004
7
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. 53 62
11443543 2001
8
Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. 53 62
11148813 2000
9
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 53 62
10756233 2000
10
Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. 53 62
9856836 1998
11
Eosinophil granule proteins expressed in ocular cicatricial pemphigoid. 53 62
9602632 1998
12
[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis]. 53 62
9759406 1998
13
Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. 53 62
8648032 1996
14
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. 53 62
8612470 1995
15
Ligneous Conjunctivitis Secondary to Viral Conjunctivitis. 62
36459582 2023
16
The effect of topical steroids and non-steroidal anti inflammatory drugs on epiphora of unknown cause: Optical Coherence Tomography Study. 62
36470407 2022
17
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. 62
36082590 2022
18
Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice. 62
35854650 2022
19
Delineating septo-optic dysplasia. 62
36200678 2022
20
Demographic profile of patients seeking teleophthalmology consultations through e-Sanjeevani: Retrospective analysis of 5138 patients from North India. 62
36453323 2022
21
Papillary conjunctivitis presenting months after permanent eyebrow tattooing. 62
36407011 2022
22
Updates of ocular involvement in granulomatosis with polyangiitis. 62
36473987 2022
23
Monkeypox as an emerging infectious disease: the ophthalmic implications. 62
36216412 2022
24
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials. 62
36471215 2022
25
Outpatient human coronavirus associated conjunctivitis in India. 62
36209621 2022
26
Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. 62
36471327 2022
27
Accuracy of the International Classification of Diseases, 9th Revision for Identifying Infantile Eye Disease. 62
34821545 2022
28
Deep sequencing analysis of clinical samples from patients with acute infectious conjunctivitis during the COVID-19 delta surge in Madurai, India. 62
36242841 2022
29
Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions. 62
35369809 2022
30
A survey of allergic conjunctivitis in children in China. 62
36470950 2022
31
Efficacy of Proactive Topical Antihistamine Use in Patients with Seasonal Allergic Conjunctivitis. 62
36244054 2022
32
Severe Acute Respiratory Syndrome Coronavirus 2-Associated Blepharoconjunctivitis and Erythema Multiforme-Like Rash in a Young Man. 62
36198619 2022
33
Signs and symptoms of COVID-19 in patients with multiple sclerosis. 62
36086905 2022
34
The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease - A pilot prospective clinical trial. 62
35864019 2022
35
Concurrent pigeon paramyxovirus-1 and Acinetobacter baumannii infection in a fatal case of pneumonia. 62
35290154 2022
36
Differential expression of long non-coding RNAs under Peste des petits ruminants virus (PPRV) infection in goats. 62
35129076 2022
37
Multimodal imaging in the diagnosis and management of ophthalmia nodosa. 62
36324631 2022
38
Associations between conjunctivitis and ambient PM2.5 and physical activity: A nationwide prospective cohort study. 62
35981585 2022
39
[First- and second-line hospital management of ophthalmologic emergencies: Clinical pathway study of 1360 patients]. 62
36470749 2022
40
Spectrum and resistance in bacterial infections of the ocular surface in a German tertiary referral center 2009-2019. 62
35687174 2022
41
Ocular Injuries Related to Grooming Visits in Dogs: 161 Cases (2004-2020). 62
36315866 2022
42
High-Resolution Imaging of the Ocular Vasculature of Conjunctivitis in Mice Using Highly Bright Polymer Dots. 62
36027786 2022
43
What Signs and Symptoms Are Suggestive of Bacterial Conjunctivitis? 62
36334957 2022
44
Distribution and genetic diversity of Feline calicivirus in Moscow metropolitan area. 62
36448438 2022
45
In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis. 62
36346478 2022
46
Ocular Side Effects of Bisphosphonates: A Review of Literature. 62
36409537 2022
47
Pathogenicity of a novel classical swine fever LOM vaccine-derived virus isolated on Jeju Island, South Korea. 62
35944180 2022
48
Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study. 62
36370717 2022
49
Hyper-Reflective Outer Nuclear Layer (HONL) in Vogt-Koyanagi-Harada Disease and Sympathetic Ophthalmia. 62
36332138 2022
50
Occurrence of Chlamydia spp. in Conjunctival Samples of Stray Cats in Timișoara Municipality, Western Romania. 62
36363779 2022

Variations for Conjunctivitis

Expression for Conjunctivitis

Search GEO for disease gene expression data for Conjunctivitis.

Pathways for Conjunctivitis

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 CCL11 CCL2 CXCL8 ICAM1 IFNG IL10
2
Show member pathways
13.92 CCL11 CCL2 CXCL8 IL10 IL13 IL2
3 13.86 TNF PLG IL6 IL5 IL33 IL2
4
Show member pathways
13.77 TNF TLR4 IL6 IL5 IL4 IL33
5
Show member pathways
13.68 TNF IL6 IL5 IL4 IL2 IL13
6
Show member pathways
13.57 CCL11 CCL2 CXCL8 IL10 IL13 IL2
7
Show member pathways
13.44 TNF IL6 IL5 IL4 IL2 IL13
8
Show member pathways
13.44 TNF IL6 IL5 IL4 IL33 IL2
9
Show member pathways
12.95 TNF TLR4 TLR3 IL6 IL2 CXCL8
10
Show member pathways
12.81 TNF IL6 IL5 IL4 IL2 IL13
11
Show member pathways
12.78 TNF TLR4 TLR3 IL6 IL2
12
Show member pathways
12.76 TNF PLG IL6 IL2 IL10 IFNG
13 12.74 TNF TLR3 IL4 IL2 IL10 IFNG
14
Show member pathways
12.68 CXCL8 IL6 NLRP3 TLR3 TLR4 TNF
15
Show member pathways
12.61 TNF TLR4 IL6 IL4 IFNG CXCL8
16
Show member pathways
12.5 TLR4 TLR3 IFNG CXCL8
17
Show member pathways
12.48 TNF TLR4 TLR3 IL6 IFNG CXCL8
18
Show member pathways
12.35 TNF IL6 CXCL8 CCL2
19 12.34 TNF TLR4 TLR3 IL6 IFNG
20
Show member pathways
12.33 IFNG IL10 IL2 IL4 IL5 TNF
21 12.32 CXCL8 IL10 IL13 IL6 TNF
22 12.29 TNF IL6 IL4 IL13 IL10 IFNG
23
Show member pathways
12.28 TNF IL4 IL2 IFNG
24 12.21 TNF IL6 IL5 IL4 IL2 IL10
25
Show member pathways
12.19 TLR4 TLR3 IL5 IL2 IL13
26
Show member pathways
12.12 TNF TLR4 TLR3 IL6 IL2 IL10
27 12.08 CXCL8 IFNG IL10 IL13 IL2 IL4
28
Show member pathways
12.05 TLR4 TLR3 IL6 IL4 IFNG
29 12.02 IL6 IL10 CXCL8 CCL2
30
Show member pathways
12.01 TLR4 IL6 ICAM1 CXCL8
31 12 TNF IL5 IL4 IL33 IL2 IL13
32 11.99 TNF TLR4 IL6 ICAM1 CXCL8 CCL2
33 11.98 TLR4 TLR3 IL6 IL2 IL10 IFNG
34 11.97 IL6 IL5 IL4 IL2 IL13 IFNG
35 11.95 TNF IL6 IL2 IL10 IFNG
36 11.94 CCL11 CCL2 CXCL8 ICAM1 IL10 IL13
37
Show member pathways
11.93 CXCL8 IFNG IL2 IL4 IL5 TNF
38 11.93 TNF TLR4 IL6 IL4 IL2 IL10
39
Show member pathways
11.92 IL6 IGHE CXCL8 CCL2
40 11.9 TLR4 IL2 CXCL8
41 11.9 CCL2 CXCL8 IFNG IL10 IL2 IL4
42
Show member pathways
11.89 TNF IL6 IL2 IFNG ICAM1 CXCL8
43 11.88 TNF TLR4 IL6 IL10 ICAM1 CXCL8
44 11.87 IL6 IL4 IL2 IFNG
45 11.87 CCL2 CXCL8 ICAM1 IFNG IL2 IL4
46
Show member pathways
11.84 TNF NLRP3 IFNG
47 11.83 CCL11 CCL2 CXCL8 IL13 IL4 IL5
48 11.82 TNF TLR4 IL6 IL10
49 11.8 IL5 IL4 IL10 CCL11
50
Show member pathways
11.79 IL6 CCL2 CCL11

GO Terms for Conjunctivitis

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.15 CCL11 CCL2 CXCL8 IFNG IGHE IL10
2 extracellular space GO:0005615 9.85 CCL11 CCL2 CXCL8 ICAM1 IFNG IGHE

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.67 TNF TLR4 TLR3 NLRP3 IL6 IL4
2 positive regulation of gene expression GO:0010628 10.48 CXCL8 IFNG IL13 IL33 IL4 IL6
3 signal transduction GO:0007165 10.46 TNF TLR4 TLR3 NLRP3 IL6 IL5
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.41 TNF TLR4 ICAM1 CCL2 CCL11
5 defense response to virus GO:0051607 10.37 IFNG IL33 IL6 NLRP3 TLR3
6 chemotaxis GO:0006935 10.35 RNASE3 CXCL8 CCL2 CCL11
7 defense response to bacterium GO:0042742 10.33 TNF TLR4 TLR3 RNASE3 IL10 IGHE
8 positive regulation of DNA-binding transcription factor activity GO:0051091 10.32 TNF IL6 IL5 IL10
9 positive regulation of tumor necrosis factor production GO:0032760 10.3 TLR4 TLR3 IL6 IL33 IFNG
10 cellular response to type II interferon GO:0071346 10.29 TNF TLR4 TLR3 CCL2 CCL11
11 cellular response to lipopolysaccharide GO:0071222 10.29 CCL2 CXCL8 IL10 IL6 NLRP3 TLR4
12 positive regulation of type II interferon production GO:0032729 10.28 TNF TLR4 TLR3 IL2
13 negative regulation of inflammatory response GO:0050728 10.28 IL10 IL13 IL2 IL4 NLRP3
14 defense response to Gram-positive bacterium GO:0050830 10.27 TNF RNASE3 NLRP3 IL6
15 cellular response to mechanical stimulus GO:0071260 10.27 TLR4 TLR3 IL33 IL13
16 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.27 TNF TLR4 TLR3 NLRP3 IL6
17 positive regulation of interleukin-6 production GO:0032755 10.27 TNF TLR4 TLR3 IL6 IL33 IFNG
18 response to virus GO:0009615 10.26 TNF TLR3 IFNG CCL11
19 positive regulation of interleukin-8 production GO:0032757 10.26 TNF TLR4 TLR3 IL6
20 humoral immune response GO:0006959 10.26 TNF IL6 IFNG CCL2
21 positive regulation of interleukin-1 beta production GO:0032731 10.26 TNF TLR4 NLRP3 IL6 IFNG
22 positive regulation of smooth muscle cell proliferation GO:0048661 10.24 TNF TLR4 IL6 IL13
23 extrinsic apoptotic signaling pathway GO:0097191 10.24 TNF TLR3 IL33 IFNG
24 cellular response to virus GO:0098586 10.23 TLR3 NLRP3 IL6 IFNG
25 regulation of insulin secretion GO:0050796 10.22 TNF IL6 IFNG
26 response to activity GO:0014823 10.22 TNF IL6 IL10
27 monocyte chemotaxis GO:0002548 10.22 IL6 CCL2 CCL11
28 positive regulation of interleukin-10 production GO:0032733 10.22 TLR4 IL6 IL4 IL13
29 positive regulation of cytokine production GO:0001819 10.22 IFNG IL10 IL33 TLR3 TNF
30 cellular response to amyloid-beta GO:1904646 10.21 TNF TLR4 ICAM1
31 negative regulation of type II interferon production GO:0032689 10.21 TLR4 IL33 IL10
32 positive regulation of interleukin-12 production GO:0032735 10.21 IFNG TLR3 TLR4
33 positive regulation of B cell proliferation GO:0030890 10.21 TLR4 IL5 IL4 IL2 IL13
34 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.21 IFNG IL13 IL2 IL4 IL6 TNF
35 positive regulation of nitric oxide biosynthetic process GO:0045429 10.2 TNF TLR4 IFNG
36 lipopolysaccharide-mediated signaling pathway GO:0031663 10.2 CCL2 TLR4 TNF
37 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.2 IL10 IL5 IL6 TNF
38 negative regulation of endothelial cell apoptotic process GO:2000352 10.19 IL4 IL13 IL10 ICAM1
39 liver regeneration GO:0097421 10.18 IL10 IL6 TNF
40 negative regulation of osteoclast differentiation GO:0045671 10.18 TLR4 TLR3 IL4
41 positive regulation of inflammatory response GO:0050729 10.18 TNF TLR4 TLR3 NLRP3 IL33 IL2
42 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.17 TNF TLR4 IL6
43 negative regulation of neurogenesis GO:0050768 10.16 CCL11 IL6 TNF
44 macrophage activation GO:0042116 10.15 IL13 IL4 TLR4
45 positive regulation of macrophage activation GO:0043032 10.15 TLR4 IL33 IL13 IL10
46 eosinophil chemotaxis GO:0048245 10.14 HRH1 CCL2 CCL11
47 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.14 TLR4 IL33 IFNG CCL2
48 positive regulation of neuroinflammatory response GO:0150078 10.1 TNF IL6 IL33
49 microglial cell activation GO:0001774 10.1 TNF TLR3 IL4 IL13 IFNG
50 positive regulation of chemokine production GO:0032722 10.1 IFNG IL33 IL6 TLR3 TLR4 TNF

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.65 IL6 IL5 IL4 IL2 IL10
2 cytokine activity GO:0005125 9.64 TNF IL6 IL5 IL4 IL33 IL2

Sources for Conjunctivitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....